دورية أكاديمية
Breakthrough Invasive Fungal Infections in Patients With High-Risk Hematological Disorders Receiving Voriconazole and Posaconazole Prophylaxis: A Systematic Review.
| العنوان: | Breakthrough Invasive Fungal Infections in Patients With High-Risk Hematological Disorders Receiving Voriconazole and Posaconazole Prophylaxis: A Systematic Review. |
|---|---|
| المؤلفون: | Boutin CA; Department of Microbiology, Infectious Diseases and Immunology, Faculty of Medicine, Université de Montréal, Montreal, Quebec, Canada.; Division of Infectious Diseases, Department of Medicine, Centre hospitalier de l'Université de Montréal, Montreal, Quebec, Canada., Durocher F; Department of Microbiology, Infectious Diseases and Immunology, Faculty of Medicine, Université de Montréal, Montreal, Quebec, Canada., Beauchemin S; Centre de Recherche de l'Hôpital Maisonneuve-Rosemont, Montreal, Quebec, Canada., Ziegler D; Direction de l'enseignement et de l'Académie, Bibliothèque, Centre hospitalier de l'Université de Montréal, Montreal, Quebec, Canada., Abou Chakra CN; Centre de Recherche de l'Hôpital Maisonneuve-Rosemont, Montreal, Quebec, Canada., Dufresne SF; Department of Microbiology, Infectious Diseases and Immunology, Faculty of Medicine, Université de Montréal, Montreal, Quebec, Canada.; Centre de Recherche de l'Hôpital Maisonneuve-Rosemont, Montreal, Quebec, Canada.; Division of Infectious Diseases and Clinical Microbiology, Department of Medicine, Hôpital Maisonneuve-Rosemont, Centre Intégré Universitaire de Santé et de Services Sociaux de l'Est-de-l'Île-de-Montréal, Montréal, Québec, Canada. |
| المصدر: | Clinical infectious diseases : an official publication of the Infectious Diseases Society of America [Clin Infect Dis] 2024 Jul 19; Vol. 79 (1), pp. 151-160. |
| نوع المنشور: | Systematic Review; Journal Article |
| اللغة: | English |
| بيانات الدورية: | Publisher: Oxford University Press Country of Publication: United States NLM ID: 9203213 Publication Model: Print Cited Medium: Internet ISSN: 1537-6591 (Electronic) Linking ISSN: 10584838 NLM ISO Abbreviation: Clin Infect Dis Subsets: MEDLINE |
| أسماء مطبوعة: | Publication: Jan. 2011- : Oxford : Oxford University Press Original Publication: Chicago, IL : The University of Chicago Press, c1992- |
| مواضيع طبية MeSH: | Antifungal Agents*/therapeutic use , Invasive Fungal Infections*/prevention & control , Invasive Fungal Infections*/drug therapy , Voriconazole*/therapeutic use , Hematologic Diseases*/complications , Triazoles*/therapeutic use, Humans ; Drug Resistance, Fungal ; Aspergillus/drug effects |
| مستخلص: | Background: Primary antifungal prophylaxis with mold-active azoles is used to prevent invasive fungal infections in patients with high-risk hematological disorders; however, breakthrough infections occur, and the reasons for treatment failure are still not fully understood. To help inform clinical decisions, we sought to define microbiological, clinical, and pharmacological characteristics of proven and probable breakthrough invasive fungal infections (bIFIs) in patients with high-risk hematological disorders receiving voriconazole or posaconazole prophylaxis. Methods: We performed a systematic review of the literature following Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines. The search strategy was last conducted on 19 April 2023. Results: We assessed 5293 studies for eligibility, and 300 were selected for data extraction. These studies described 1076 cases of bIFIs occurring under voriconazole (42.5%) or posaconazole (57.5%). The most commonly found pathogens were Aspergillus (40%), Mucorales (20%), Candida (18%), and Fusarium (9%) species. Mucorales were more frequent among voriconazole-emerging cases, whereas Aspergillus and Fusarium were more prevalent among posaconazole-emerging cases. Definitive, putative, or probable antifungal resistance was found in 31% of cases. Therapeutic drug monitoring showed subtherapeutic azole concentration in 32 of 90 (36%) cases. Infection-related mortality was reported in 117 cases and reached 35%. Conclusions: In our systemic review, the most common bIFIs were aspergillosis, mucormycosis, candidiasis, and fusariosis. Antifungal resistance explains only a minority of cases. Subtherapeutic prophylaxis was frequent but rarely reported. Prospective studies are needed to better understand these infections and to establish optimal management. Competing Interests: Potential conflicts of interest . S. F. D. has received honoraria for consultancy and research funding from AVIR Pharma Inc and Merck & Co. All other authors report no potential conflicts. All authors have submitted the ICMJE Form for Disclosure of Potential Conflicts of Interest. Conflicts that the editors consider relevant to the content of the manuscript have been disclosed. (© The Author(s) 2024. Published by Oxford University Press on behalf of Infectious Diseases Society of America.) |
| References: | Med Mycol. 2019 Apr 1;57(Supplement_2):S127-S137. (PMID: 30816979) Pathogens. 2020 Nov 07;9(11):. (PMID: 33171713) Lancet Microbe. 2023 Jun;4(6):e470-e480. (PMID: 37121240) BMJ. 2021 Mar 29;372:n71. (PMID: 33782057) Diagn Microbiol Infect Dis. 2012 Aug;73(4):293-300. (PMID: 22789847) FEMS Yeast Res. 2009 Jun;9(4):626-33. (PMID: 19385998) J Fungi (Basel). 2023 May 19;9(5):. (PMID: 37233303) Clin Infect Dis. 2020 Sep 12;71(6):1367-1376. (PMID: 31802125) Haematologica. 2006 Aug;91(8):1068-75. (PMID: 16885047) J Fungi (Basel). 2023 Jul 28;9(8):. (PMID: 37623569) J Antimicrob Chemother. 2016 Sep;71(9):2634-41. (PMID: 27317443) Clin Microbiol Infect. 2021 Apr;27(4):538-549. (PMID: 33418022) Lancet Infect Dis. 2021 Dec;21(12):e375-e386. (PMID: 34419208) Mycoses. 2020 Oct;63(10):1021-1032. (PMID: 32744334) Clin Infect Dis. 2017 Jun 1;64(11):1619-1621. (PMID: 28199491) Antimicrob Agents Chemother. 2021 May 18;65(6):. (PMID: 33820766) Clin Microbiol Infect. 2018 May;24 Suppl 1:e1-e38. (PMID: 29544767) Open Forum Infect Dis. 2023 Aug 07;10(9):ofad424. (PMID: 37674634) J Fungi (Basel). 2021 Mar 17;7(3):. (PMID: 33802827) Clin Infect Dis. 2016 Aug 15;63(4):e1-e60. (PMID: 27365388) N Engl J Med. 2004 Feb 26;350(9):950-2. (PMID: 14985500) J Infect. 2023 Jul;87(1):46-53. (PMID: 37201859) Open Forum Infect Dis. 2021 Nov 23;8(11):ofab502. (PMID: 35559121) Mycoses. 2014 Nov;57(11):645-51. (PMID: 24963554) Clin Microbiol Infect. 2019 Jan;25(1):26-34. (PMID: 30036666) Clin Infect Dis. 2005 Sep 1;41(5):634-53. (PMID: 16080086) Lancet Infect Dis. 2019 Dec;19(12):e405-e421. (PMID: 31699664) Pharmacotherapy. 2023 Oct;43(10):1043-1050. (PMID: 37459118) Clin Infect Dis. 2010 Apr 15;50(8):1091-100. (PMID: 20218877) Mycoses. 2019 Sep;62(9):716-729. (PMID: 31254420) |
| معلومات مُعتمدة: | AVIR Pharma Inc |
| فهرسة مساهمة: | Keywords: breakthrough; invasive fungal infections; posaconazole; prophylaxis; voriconazole |
| المشرفين على المادة: | 0 (Antifungal Agents) 6TK1G07BHZ (posaconazole) JFU09I87TR (Voriconazole) 0 (Triazoles) |
| تواريخ الأحداث: | Date Created: 20240516 Date Completed: 20240719 Latest Revision: 20240721 |
| رمز التحديث: | 20240721 |
| مُعرف محوري في PubMed: | PMC11259221 |
| DOI: | 10.1093/cid/ciae203 |
| PMID: | 38752732 |
| قاعدة البيانات: | MEDLINE |
Full Text Finder | تدمد: | 1537-6591 |
|---|---|
| DOI: | 10.1093/cid/ciae203 |